{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:13:25Z","timestamp":1788146005816,"version":"build-2803163510"},"reference-count":74,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Chronic coronary syndrome (CCS) is a major source of morbidity and healthcare utilization, and a substantial proportion of patients continue to experience angina despite contemporary revascularization and guideline-directed medical therapy. Trimetazidine, a metabolic anti-ischemic agent that does not affect heart rate or blood pressure, has been used for decades as a non-hemodynamic add-on. Its position in international guidelines, however, has shifted. We aimed to synthesize current evidence on the clinical efficacy, safety, and guideline status of trimetazidine in CCS and coronary artery disease (CAD) and to delineate clinical circumstances in which a symptom-directed trial may be considered. Methods: We performed a structured narrative review of randomized controlled trials, network and conventional meta-analyses, and large observational studies indexed in PubMed\/MEDLINE, Embase, and the Cochrane Library between January 1990 and March 2026. Reference lists of eligible articles, international clinical practice guidelines, and regulatory communications from European and national agencies were also examined. Results: Across pooled analyses, trimetazidine modestly but reproducibly improved exercise tolerance and reduced angina frequency and short-acting nitrate use, with efficacy comparable to other non\u2013heart-rate-lowering antianginal agents. Improvements in left ventricular function were reported in small, single-center studies in ischemic cardiomyopathy and selected high-risk subgroups; however, these findings have not been validated in contemporary large-scale trials, and their clinical significance against modern guideline-directed therapy is unknown. The ATPCI trial confirmed safety but showed no reduction in major adverse cardiovascular events after percutaneous coronary intervention. Rare extrapyramidal effects prompted the 2012 European Medicines Agency referral and several prescribing restrictions. Conclusions: Trimetazidine remains a reasonable symptom-directed adjunct for residual angina in carefully selected CCS patients, particularly those in whom further hemodynamic up-titration is limited or poorly tolerated. The 2024 ESC class IIb recommendation may partly reflect a broader emphasis on prognostic benefit, although the neutral post-PCI outcome evidence and regulatory safety restrictions also support a more cautious position.<\/jats:p>","DOI":"10.3390\/ph19091370","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:08:58Z","timestamp":1788142138000},"page":"1370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trimetazidine in Chronic Coronary Syndrome and Coronary Artery Disease: A Narrative Review of Clinical Efficacy, Safety, and Current Guideline Position"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-456X","authenticated-orcid":false,"given":"Daniel Miron","family":"Brie","sequence":"first","affiliation":[{"name":"Cardiovascular Disease Institute Timisoara, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-9601","authenticated-orcid":false,"given":"Cristian","family":"Morno\u0219","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Institute Timisoara, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"},{"name":"Department of Cardiology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"T\u00eerziu","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Institute Timisoara, Gheorghe Adam Street, No. 13A, 300310 Timisoara, Romania"},{"name":"Department of Functional Sciences, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania"},{"name":"Center of ImmunoPhysiology and Biotechnologies (CIF-BIOTECH), Department of Functional Sciences, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9387-1141","authenticated-orcid":false,"given":"Roxana","family":"Popescu","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania"},{"name":"ANAPATMOL Research Center, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4078-1537","authenticated-orcid":false,"given":"Alina Didu\u021ba","family":"Brie","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania"},{"name":"ANAPATMOL Research Center, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania"},{"name":"\u201cLouis \u021aurcanu\u201d Emergency Children Hospital, Doctor Iosif Nemoianu Street, No. 2, 300011 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the Management of Chronic Coronary Syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ahj.2018.12.015","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the EfficAcy and Safety of Trimetazidine in Patients with Angina Pectoris Having Been Treated by Percutaneous Coronary Intervention (ATPCI Study): Rationale, Design, and Baseline Characteristics","volume":"209","author":"Ferrari","year":"2019","journal-title":"Am. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal Medical Therapy with or without PCI for Stable Coronary Disease","volume":"356","author":"Boden","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial Invasive or Conservative Strategy for Stable Coronary Disease","volume":"382","author":"Maron","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","article-title":"Percutaneous Coronary Intervention in Stable Angina (ORBITA): A Double-Blind, Randomised Controlled Trial","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003495-199958010-00016","article-title":"Trimetazidine: A Review of Its Use in Stable Angina Pectoris and Other Coronary Conditions","volume":"58","author":"McClellan","year":"1999","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/14656566.2.5.857","article-title":"Trimetazidine for Stable Angina Pectoris","volume":"2","author":"Cross","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism from Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC Guidelines on the Management of Stable Coronary Artery Disease","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_12","unstructured":"EAM (2012). European Medicines Agency Recommends Restricting Use of Trimetazidine-Containing Medicines (Article 31 Referral, EMA\/CHMP\/417861\/2012), EMA."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.amjcard.2006.07.005","article-title":"Role of Trimetazidine in Management of Ischemic Cardiomyopathy","volume":"98","author":"Kaski","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"116479","DOI":"10.1016\/j.bcp.2024.116479","article-title":"Trimetazidine Attenuates Ischemia\/Reperfusion-Induced Myocardial Ferroptosis by Modulating the Sirt3\/Nrf2-GSH System and Reducing Oxidative\/Nitrative Stress","volume":"229","author":"Tan","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"178376","DOI":"10.1016\/j.ejphar.2025.178376","article-title":"Trimetazidine Alleviates Heart Failure after Myocardial Infarction by Promoting PINK1\/Parkin-Mediated Mitophagy and Suppressing GPX4-Dependent Ferroptosis","volume":"1008","author":"Wang","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_16","first-page":"175","article-title":"A Drug Review of Trimetazidine on Its Role as Add-on Therapy in Stable Angina","volume":"7","author":"Rajasekar","year":"2020","journal-title":"Int. J. Clin. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","article-title":"Myocardial Substrate Metabolism in the Normal and Failing Heart","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial Fatty Acid Metabolism in Health and Disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ehjcvp\/pvv051","article-title":"The Role of Trimetazidine in Cardiovascular Disease: Beyond an Anti-Anginal Agent","volume":"2","author":"McCarthy","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00019501-200304000-00010","article-title":"Efficacy and Tolerability of Trimetazidine in Stable Angina: A Meta-Analysis of Randomized, Double-Blind, Controlled Trials","volume":"14","author":"Marzilli","year":"2003","journal-title":"Coron. Artery Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40256-025-00724-1","article-title":"Trimetazidine in Cardiovascular Disease and beyond: A Comprehensive Review","volume":"25","author":"Goel","year":"2025","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40261-014-0170-9","article-title":"Effect of Trimetazidine on Recurrent Angina Pectoris and Left Ventricular Structure in Elderly Multivessel Coronary Heart Disease Patients with Diabetes Mellitus after Drug-Eluting Stent Implantation: A Single-Centre, Prospective, Randomized, Double-Blind Study at 2-Year Follow-Up","volume":"34","author":"Xu","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1556\/650.2020.31704","article-title":"Clinical Effect of Various Trimetazidine Formulations in Chronic Coronary Syndrome","volume":"161","author":"Nagy","year":"2020","journal-title":"Orvosi Hetil."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000332369","article-title":"Efficacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris: A Network Meta-Analysis","volume":"120","author":"Danchin","year":"2011","journal-title":"Cardiology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ijcard.2014.10.149","article-title":"The Efficacy of Trimetazidine on Stable Angina Pectoris: A Meta-Analysis of Randomized Clinical Trials","volume":"177","author":"Peng","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/clc.20888","article-title":"Evaluation of Trimetazidine in Angina Pectoris by Echocardiography and Radionuclide Angiography: A Meta-Analysis of Randomized, Controlled Trials","volume":"34","author":"Hu","year":"2011","journal-title":"Clin. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1053\/euhj.2001.2896","article-title":"Combination Treatment of Stable Effort Angina Using Trimetazidine and Metoprolol: Results of a Randomized, Double-Blind, Multicentre Study (TRIMPOL II)","volume":"22","author":"Szwed","year":"2001","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.1994.tb04276.x","article-title":"Trimetazidine: A New Concept in the Treatment of Angina. Comparison with Propranolol in Patients with Stable Angina (TEMS)","volume":"37","author":"Detry","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/hrt.78.4.353","article-title":"Combination Treatment with Trimetazidine and Diltiazem in Stable Angina Pectoris","volume":"78","author":"Manchanda","year":"1997","journal-title":"Heart"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"134050","DOI":"10.1016\/j.ijcard.2025.134050","article-title":"COMBINE Angina Investigators. Early Combination Therapy with Trimetazidine Rapidly Improves Symptoms and Quality of Life in Patients Recently Diagnosed with Stable Angina: The COMBINE Angina Study","volume":"446","author":"Marzilli","year":"2026","journal-title":"Int. J. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF)","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of Ranolazine with Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients with Severe Chronic Angina: A Randomized Controlled Trial (CARISA)","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal Efficacy of Ranolazine When Added to Treatment with Amlodipine: The ERICA Trial","volume":"48","author":"Stone","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of Ranolazine on Recurrent Cardiovascular Events in Patients with Non-ST-Elevation Acute Coronary Syndromes: The MERLIN-TIMI 36 Randomized Trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/oxfordjournals.eurheartj.a059685","article-title":"Therapeutic Value of a Cardioprotective Agent in Patients with Severe Ischaemic Cardiomyopathy","volume":"11","author":"Brottier","year":"1990","journal-title":"Eur. Heart J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jacc.2006.03.060","article-title":"A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients with Heart Failure","volume":"48","author":"Fragasso","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1053\/euhj.2001.2653","article-title":"Effects of Trimetazidine on the Contractile Response of Chronically Dysfunctional Myocardium to Low-Dose Dobutamine in Ischaemic Cardiomyopathy","volume":"22","author":"Belardinelli","year":"2001","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.108.778019","article-title":"Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy","volume":"118","author":"Tuunanen","year":"2008","journal-title":"Circulation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/hrt.2003.031310","article-title":"Long Term Cardioprotective Action of Trimetazidine and Potential Effect on the Inflammatory Process in Patients with Ischaemic Dilated Cardiomyopathy","volume":"91","author":"Taccardi","year":"2005","journal-title":"Heart"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/HJR.0b013e328304feec","article-title":"Trimetazidine Potentiates the Effects of Exercise Training in Patients with Ischemic Cardiomyopathy Referred for Cardiac Rehabilitation","volume":"15","author":"Belardinelli","year":"2008","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"O17","DOI":"10.1016\/S1520-765X(01)90150-6","article-title":"Trimetazidine and Left Ventricular Ischaemic Dysfunction: An Overview of Clinical Evidence","volume":"3","author":"Chierchia","year":"2001","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2011.11.027","article-title":"Additional Use of Trimetazidine in Patients with Chronic Heart Failure: A Meta-Analysis","volume":"59","author":"Zhang","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/hrt.2010.208751","article-title":"Trimetazidine: A Meta-Analysis of Randomised Controlled Trials in Heart Failure","volume":"97","author":"Gao","year":"2011","journal-title":"Heart"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_48","first-page":"196","article-title":"Effect of Trimetazidine on Diabetic Patients with Coronary Heart Diseases: A Meta-Analysis of Randomized, Controlled Trials","volume":"35","author":"Lin","year":"2020","journal-title":"Chin. Med. Sci. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2840-2-16","article-title":"Trimetazidine Improves Left Ventricular Function in Diabetic Patients with Coronary Artery Disease: A Double-Blind Placebo-Controlled Study","volume":"2","author":"Rosano","year":"2003","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_50","first-page":"867","article-title":"Assessment of Anti-Ischemic and Antianginal Effect at Trough Plasma Concentration and Safety of Trimetazidine MR 35 Mg in Patients with Stable Angina Pectoris: A Multicenter, Double-Blind, Placebo-Controlled Study (TIGER)","volume":"57","author":"Sellier","year":"2003","journal-title":"Int. J. Clin. Pract."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lin, X., Ma, A., Zhang, W., Lu, Q., Sun, C., Tian, H., Lei, X., and Bai, X. (2013). Cardioprotective effects of atorvastatin plus trimetazidine in percutaneous coronary intervention. Pak. J. Med. Sci., 29.","DOI":"10.12669\/pjms.292.2937"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary Microvascular Dysfunction","volume":"356","author":"Camici","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1093\/eurheartj\/ehaa503","article-title":"An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries","volume":"41","author":"Kunadian","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/CIRCULATIONAHA.116.024534","article-title":"Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the next Decade","volume":"135","author":"Pepine","year":"2017","journal-title":"Circulation"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Ilic, I., Timcic, S., Milosevic, M., Boskovic, S., Odanovic, N., Furtula, M., Dobric, M., Aleksandric, S., and Otasevic, P. (2023). The ImPAct of Trimetazidine on MicrOcirculation after Stenting for Stable Coronary Artery Disease (PATMOS Study). Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1112198"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1016\/j.jacc.2018.09.006","article-title":"Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial","volume":"72","author":"Ford","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","first-page":"2440","article-title":"Trimetazidine in Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Cross-over Trial","volume":"10","author":"Geurkink","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0140-6736(20)31790-6","article-title":"Efficacy and Safety of Trimetazidine after Percutaneous Coronary Intervention (ATPCI): A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"396","author":"Ferrari","year":"2020","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"14J","DOI":"10.1016\/j.amjcard.2006.07.003","article-title":"Clinical Benefits of a Metabolic Approach with Trimetazidine in Revascularized Patients with Angina","volume":"98","author":"Danchin","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/oxfordjournals.eurheartj.a060322","article-title":"Myocardial Protection during Percutaneous Transluminal Coronary Angioplasty: Effects of Trimetazidine","volume":"13","author":"Kober","year":"1992","journal-title":"Eur. Heart J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"ehab724.1220","DOI":"10.1093\/eurheartj\/ehab724.1220","article-title":"Trimetazidine as Adjunctive Therapy for Decreasing Major Adverse Cardiac Events in Coronary Artery Disease Patients Undergoing Reperfusion Strategy: A Meta-Analysis of Randomized Controlled Trials","volume":"42","author":"Saroca","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"Ranolazine in Patients with Incomplete Revascularisation after Percutaneous Coronary Intervention (RIVER-PCI): A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"387","author":"Weisz","year":"2016","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dy, A.M.B., Limjoco, L.L.G., and Jamora, R.D.G. (2020). Trimetazidine-Induced Parkinsonism: A Systematic Review. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00044"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.20574","article-title":"Trimetazidine: A New Cause for Drug-Induced Parkinsonism?","volume":"20","author":"Sommet","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kim, S., Yu, Y.M., Kwon, J., Jeong, K.H., Lee, J.S., and Lee, E. (2020). Trimetazidine Use and the Risk of Parkinsonism: A Nationwide Population-Based Study. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17197256"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000497613","article-title":"Association between Trimetazidine and Parkinsonism: A Population-Based Study","volume":"52","author":"Kwon","year":"2019","journal-title":"Neuroepidemiology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1472-8206.2011.01008.x","article-title":"Extrapyramidal Adverse Drug Reactions Associated with Trimetazidine: A Series of 21 Cases","volume":"26","author":"Masmoudi","year":"2012","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_68","unstructured":"Agency, W.A.-D. (2025). The Prohibited List 2026\u2014Class S4.4 (Metabolic Modulators), Trimetazidine, WADA."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jcpt.12799","article-title":"A Drug Utilization Study to Evaluate the Effectiveness of Risk Minimization Measures for Trimetazidine in France, Hungary, Romania and Spain","volume":"44","author":"Ehlken","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure (SIGNIFY)","volume":"371","author":"Fox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ferrari, R., Gowdak, L.H.W., Padilla, F., Quek, D.K.L., Ray, S., Rosano, G., Indolfi, C., and Perrone Filardi, P. (2025). The European Society of Cardiology 2024 Guidelines on Chronic Coronary Syndromes: A Critical Appraisal. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041161"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ajabnoor, A., and Mukhtar, A. (2022). Effect of Trimetazidine on the Functional Capacity of Ischemic Heart Disease Patients Not Suitable for Revascularization: Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263932"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:13:36Z","timestamp":1788142416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/9\/1370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":74,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ph19091370"],"URL":"https:\/\/doi.org\/10.3390\/ph19091370","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}